Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01693731 · ClinicalTrials.gov registry record
Oral Health in Breast Cancer Survivors on Aromatase Inhibitors
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 300
- Enrollment target
NCT01693731: Completed study, sponsored by University of Michigan.
NCT01693731 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01693731 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how aromatase inhibitors (AIs) such as Arimidex, Aromasin or Femara affect a woman's oral health and oral health related quality of life. Patients, dental professionals and medical oncologists will benefit from a greater understanding of the best oral care follow up practices of breast cancer survivors using aromatase inhibitors.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-03 |
What the finished NCT01693731 record still lists
NCT01693731 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01693731 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01693731 about?
NCT01693731 is a clinical study titled "Oral Health in Breast Cancer Survivors on Aromatase Inhibitors". The purpose of this study is to determine how aromatase inhibitors (AIs) such as Arimidex, Aromasin or Femara affect a woman's oral health and oral health related quality of life. Patients, dental professionals and medical oncologists will benefit from a greater understanding of the best oral care f...
What is the current status of trial NCT01693731?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2012-04. Estimated completion is 2015-03.
Who is sponsoring clinical trial NCT01693731?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia